Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$7.9 million.

  • Enanta Pharmaceuticals' Free Cash Flow rose 5893.24% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.2 million, marking a year-over-year increase of 6673.84%. This contributed to the annual value of -$32.2 million for FY2025, which is 6673.84% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Free Cash Flow of -$7.9 million as of Q3 2025, which was up 5893.24% from $17.4 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Free Cash Flow peaked at $17.4 million during Q2 2025, and registered a low of -$38.8 million during Q4 2022.
  • Over the past 5 years, Enanta Pharmaceuticals' median Free Cash Flow value was -$21.1 million (recorded in 2021), while the average stood at -$20.2 million.
  • In the last 5 years, Enanta Pharmaceuticals' Free Cash Flow crashed by 52812.43% in 2021 and then skyrocketed by 18270.26% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Free Cash Flow stood at -$13.6 million in 2021, then tumbled by 184.56% to -$38.8 million in 2022, then skyrocketed by 33.56% to -$25.8 million in 2023, then grew by 0.89% to -$25.5 million in 2024, then surged by 68.89% to -$7.9 million in 2025.
  • Its last three reported values are -$7.9 million in Q3 2025, $17.4 million for Q2 2025, and -$16.0 million during Q1 2025.